H.C. Wainwright Reiterates Buy Rating on Microbot Medical (MBOT)

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $12.00 price target on Microbot Medical (NASDAQ: MBOT).

The analyst commented: "Yesterday, Microbot Medical announced that it has partnered with a U.S. based third-party logistics (3PL) company to support the commercialization of the LIBERTY system. The 3PL company is a fully compliant and integrated fulfillment solutions provider specializing in the medical device industry, and it can provide effective and efficient order processing and the ability to maintain inventory to meet expected demand from a strategically located, climate-controlled warehouse. We note that LIBERTY is the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures. A limited market release is on track to be initiated in the U.S. in 4Q25. A broader launch is slated to occur in April 2026 during the Society of Interventional Radiology conference. The initial addressable market comprises approximately 2.5M peripheral endovascular procedures each year in the U.S. In our view, this partnership helps establish the infrastructure (inventory management and customer support) needed to support the company’s go-to-market initiatives in the coming months. We reiterate our Buy rating and $12 price target."

For an analyst ratings summary and ratings history on Microbot Medical click here. For more ratings news on Microbot Medical click here.

Shares of Microbot Medical closed at $2.88 yesterday.

You May Also Be Interested In